Evogene (EVGN) Net Margin (2012 - 2026)
Evogene (EVGN) posted Net Margin of 1757.49% for Q1 2026, down 3.95% sequentially from 1690.76% in Q4 2025, and down 164707.0% YoY from N/an in Q1 2025.
Evogene (EVGN) Net Margin (2012 - 2026) Analysis & Trends
Evogene has reported Net Margin for 15 years, with the latest figure at 1757.49% in Q1 2026.
- Quarterly Net Margin fell 164707.0% year-over-year to 1757.49% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 638.12% (down 56797.0% YoY) and the FY2025 annual result came in at 220.22%, up 7537.0% from the prior year.
- Net Margin eased to 1757.49% in Q1 2026 per EVGN's latest filing, from 1690.76% in the prior quarter.
- Over five years, Net Margin peaked at 2827.24% in Q2 2022 and troughed at 3491.56% in Q1 2022.
- A 5-year average of 359.07% and a median of 438.51% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin surged 742724 bps in 2022, then slumped 175339 bps in 2023.
- Over 5 years, Net Margin stood at 454.24% in 2022, then plunged by 151 bps to 1142.04% in 2023, then surged by 102 bps to 27.67% in 2024, then slumped by 6210 bps to 1690.76% in 2025, then declined by 4 bps to 1757.49% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 1757.49%, 1690.76%, and 1241.67% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -1,757.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,757.49% |
| Dec 31, 2025 | -1,690.76% |
| Sep 30, 2025 | 1,241.67% |
| Jun 30, 2025 | -504.75% |
| Mar 31, 2025 | -110.41% |
| Dec 31, 2024 | 27.67% |
| Sep 30, 2024 | -438.51% |
| Jun 30, 2024 | 895.70% |
| Mar 31, 2024 | -92.20% |
| Dec 31, 2023 | -1,142.04% |
| Sep 30, 2023 | -105.76% |
| Jun 30, 2023 | 1,073.85% |
| Mar 31, 2023 | -978.32% |
| Dec 31, 2022 | -454.24% |
| Sep 30, 2022 | -1,404.29% |
| Jun 30, 2022 | 2,827.24% |
| Mar 31, 2022 | -3,491.56% |
| Dec 31, 2021 | -2,370.10% |
| Sep 30, 2021 | -5,039.74% |
| Jun 30, 2021 | -4,600.00% |